Nov 17, 2025 4:30 pm EST Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Nov 6, 2025 7:00 am EST Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates
Oct 29, 2025 7:00 am EDT Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa
Oct 1, 2025 7:00 am EDT Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources
Aug 7, 2025 7:00 am EDT Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates
Jun 18, 2025 7:00 am EDT Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors
